SCHEMBL5655693

SCHEMBL5655693

COC(=O)c1cc(OC)c(OC)c2oc(C(=O)OC(C)(C)C)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.45
POLB P06746 3/20 0.45
HSD17B10 Q99714 2/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 3/20 0.40
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA13 Q8N1Q1 2/20 0.38
CA2 P00918 1/20 0.38
LMNA P02545 2/20 0.37
TSHR P16473 1/20 0.36
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
RELA Q04206 2/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657180 0.86 KDM4E (0.46) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5669321 0.84 KDM4E (0.49) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5655755 0.81 KDM4E (0.46) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5658605 0.79 KDM4E (0.44) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5659653 0.79 PDE4A (0.50) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL18384659 0.78 CA12 (0.53) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5659664 0.78 KMT2A (0.54) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5658511 0.77 MAPT (0.54) KDM4EPOLBALDH1A1CA1CA2
SCHEMBL5658621 0.76 KDM4E (0.49) KDM4EPOLBHSD17B10USP2ALDH1A1
SCHEMBL5668947 0.76 SMN1; SMN2 (0.45) KDM4EPOLBHSD17B10USP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030130-B2 Benzofuran derivatives and their use as antibacterial agents ARPIDA AG (CH) 2006-04-18 US disclosed
EP-1307445-B1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2005-12-21 EP disclosed
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents EVOLVA SA (CH) 2004-02-19 US disclosed
EP-1307445-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Arpida AG, (CH) 2003-05-07 EP disclosed
WO-2002010156-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 WO disclosed
WO-2002010157-A1 BENZOFURAN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ARPIDA AG (CH) 2002-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034047-A1 Benzofuran derivatives and their use as antibacterial agents SBDS, BPTF, DCXR KDM4E 1540/4885POLB 731/4885HSD17B10 2042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.